MX2022016515A - Nuevo inhibidor de la secrecion de acido y uso del mismo. - Google Patents

Nuevo inhibidor de la secrecion de acido y uso del mismo.

Info

Publication number
MX2022016515A
MX2022016515A MX2022016515A MX2022016515A MX2022016515A MX 2022016515 A MX2022016515 A MX 2022016515A MX 2022016515 A MX2022016515 A MX 2022016515A MX 2022016515 A MX2022016515 A MX 2022016515A MX 2022016515 A MX2022016515 A MX 2022016515A
Authority
MX
Mexico
Prior art keywords
acid secretion
secretion inhibitor
novel acid
present
novel compound
Prior art date
Application number
MX2022016515A
Other languages
English (en)
Inventor
Jung Woo Lee
Hong Chul Yoon
Kyung Mi An
Woo Jin Jeon
Da Hae Hong
Jung Ho Kim
Jae Eui Shin
Min Whan Chang
Joon Tae Park
A Rang Im
Jae Ho Heo
Chang Hee Hong
Jung Eun Park
Te Ik Sohn
Yeong Ran Yoo
In Gyu Je
Su Yeon Kang
Yoon Sung Song
Joo Yun Lee
Original Assignee
Ildong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharmaceutical Co Ltd filed Critical Ildong Pharmaceutical Co Ltd
Publication of MX2022016515A publication Critical patent/MX2022016515A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente invención proporciona un nuevo compuesto representado por la Fórmula Química 2 o una sal farmacéuticamente aceptable del mismo; el nuevo compuesto de acuerdo con la presente invención presenta un excelente efecto inhibidor de la secreción de ácido.
MX2022016515A 2020-06-17 2021-06-16 Nuevo inhibidor de la secrecion de acido y uso del mismo. MX2022016515A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200073900 2020-06-17
PCT/KR2021/007572 WO2021256861A1 (ko) 2020-06-17 2021-06-16 신규한 산 분비 억제제 및 이의 용도

Publications (1)

Publication Number Publication Date
MX2022016515A true MX2022016515A (es) 2023-01-30

Family

ID=79176045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016515A MX2022016515A (es) 2020-06-17 2021-06-16 Nuevo inhibidor de la secrecion de acido y uso del mismo.

Country Status (16)

Country Link
US (2) US11767311B2 (es)
EP (1) EP4148050A4 (es)
JP (1) JP7404561B2 (es)
KR (2) KR20210156235A (es)
CN (1) CN115884968A (es)
AU (1) AU2021293694B2 (es)
BR (1) BR112022025613A2 (es)
CA (1) CA3182882A1 (es)
CL (1) CL2022003601A1 (es)
CO (1) CO2023000396A2 (es)
DO (1) DOP2022000291A (es)
EC (1) ECSP23002606A (es)
MX (1) MX2022016515A (es)
PE (1) PE20231652A1 (es)
TW (1) TWI797645B (es)
WO (1) WO2021256861A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7404561B2 (ja) 2020-06-17 2023-12-25 イルドン ファーマシューティカル カンパニー リミテッド 新規な酸分泌抑制剤及びその用途
KR20230091056A (ko) * 2021-12-15 2023-06-22 일동제약(주) 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
WO2023113474A1 (ko) * 2021-12-15 2023-06-22 일동제약(주) 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
KR20230102353A (ko) * 2021-12-30 2023-07-07 주식회사 대웅제약 삼중음성유방암의 예방 또는 치료용 약학적 조성물
CN114539219A (zh) * 2022-03-17 2022-05-27 日照正济药业有限公司 一种富马酸伏诺拉生的制备方法
WO2023211843A1 (en) * 2022-04-25 2023-11-02 Daewoong Pharmaceutical Co., Ltd. Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions
WO2023229322A1 (ko) * 2022-05-23 2023-11-30 일동제약(주) 6-메톡시피리딘-3-일 유도체의 제조방법
WO2023229323A1 (ko) * 2022-05-23 2023-11-30 일동제약(주) 6-메톡시피리딘-3-일 유도체의 제조방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200307544A (en) * 2002-06-14 2003-12-16 Takeda Chemical Industries Ltd Imidazole compound, production method thereof and use thereof
EP1803709B1 (en) * 2004-09-30 2013-01-02 Takeda Pharmaceutical Company Limited Proton pump inhibitors
AU2006285641A1 (en) * 2005-08-30 2007-03-08 Takeda Pharmaceutical Company Limited 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
JP5207964B2 (ja) 2006-03-31 2013-06-12 武田薬品工業株式会社 酸分泌抑制薬
US8933105B2 (en) * 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
ME01598B (me) * 2008-08-27 2014-09-20 Jedinjenja pirola
CA2756086A1 (en) * 2009-03-26 2010-09-30 Takeda Pharmaceutical Company Limited Pyrazole compound
UY34880A (es) * 2012-06-27 2014-01-31 Takeda Pharmaceutical Preparación líquida
JP6343600B2 (ja) 2013-02-28 2018-06-13 武田薬品工業株式会社 スルホニルクロライド化合物の製造法
CN105693693A (zh) * 2014-11-27 2016-06-22 江苏柯菲平医药股份有限公司 一种吡咯类胃酸分泌和抑制剂化合物盐的制备
CN105985278A (zh) * 2015-01-27 2016-10-05 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN106432191A (zh) * 2015-08-10 2017-02-22 陕西合成药业股份有限公司 一种新的吡咯类衍生物、其制备方法及其在医药上的应用
KR20170113040A (ko) * 2016-03-25 2017-10-12 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염
CN109843869B (zh) * 2016-09-29 2021-07-16 江苏吉贝尔药业股份有限公司 1-[(吡啶-3-基-磺酰基)-1h-吡咯-3-基]甲胺衍生物及其药物组合物和用途
PE20200442A1 (es) 2017-07-10 2020-02-28 Takeda Pharmaceuticals Co Preparacion que comprende vonoprazan
CN110396080B (zh) * 2018-04-24 2022-07-08 广东东阳光药业有限公司 一种富马酸沃诺拉赞代谢物及其氘代物的制备方法
CN108558831B (zh) 2018-06-08 2021-07-27 上海璃道医药科技有限公司 取代吡咯-4-烷基胺类化合物及其用途
JP7404561B2 (ja) 2020-06-17 2023-12-25 イルドン ファーマシューティカル カンパニー リミテッド 新規な酸分泌抑制剤及びその用途
CN111943932B (zh) * 2020-08-06 2023-07-14 四川国康药业有限公司 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途

Also Published As

Publication number Publication date
DOP2022000291A (es) 2023-01-15
EP4148050A1 (en) 2023-03-15
KR20210156235A (ko) 2021-12-24
JP2023524172A (ja) 2023-06-08
WO2021256861A1 (ko) 2021-12-23
US20230373954A1 (en) 2023-11-23
AU2021293694B2 (en) 2023-12-21
CA3182882A1 (en) 2021-12-23
CL2022003601A1 (es) 2023-07-07
KR20210156234A (ko) 2021-12-24
PE20231652A1 (es) 2023-10-17
JP7404561B2 (ja) 2023-12-25
TW202325702A (zh) 2023-07-01
US20230192650A1 (en) 2023-06-22
EP4148050A4 (en) 2023-10-25
BR112022025613A2 (pt) 2023-01-17
AU2021293694A1 (en) 2023-01-19
CN115884968A (zh) 2023-03-31
TWI797645B (zh) 2023-04-01
TW202214588A (zh) 2022-04-16
CO2023000396A2 (es) 2023-02-27
US11767311B2 (en) 2023-09-26
ECSP23002606A (es) 2023-03-31
KR102432523B1 (ko) 2022-08-16

Similar Documents

Publication Publication Date Title
MX2022016515A (es) Nuevo inhibidor de la secrecion de acido y uso del mismo.
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
CR20210247A (es) Nuevos compuestos heterocíclicos
TN2020000081A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
EA017861B9 (ru) Способ получения 4-оксохинолинового соединения
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
MX2021007017A (es) Inhibidor de la 15-pgdh.
CR20220251A (es) Nuevos derivados de metilquinazolinona
SG11201810725WA (en) Novel β-lactamase inhibitors
CR20220116A (es) Compuestos heterocíclicos
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
MX2021001904A (es) Formas solidas de benzoxaborol sustituido y composiciones de las mismas.
CR20200643A (es) Nuev0s compuestos de piridina y pirazina com0 inhibidores del receptor connabinoide 2
MX2020008982A (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico.
MX2020004588A (es) Inhibidor de proteasa de doble cabeza.
MX2022008665A (es) Nuevo derivado de pirazol.
UA96149C2 (en) Method for producing 4-oxoquinoline compound
MX2022004912A (es) Novedoso compuesto de anillo condensado sustituido.
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
AU2019408336A8 (en) Phenylpyrrolidine compound and use thereof
SG11201803867TA (en) Sodium channel blocker
ZA202205158B (en) Polypeptide having mmp2-inhibitory effect
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.